Literature DB >> 28239644

HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells.

Qingxue Li1, Wei Bu1, Erin Gabriel2, Fiona Aguilar1, Yo Hoshino1, Hiroko Miyadera3,4, Christoph Hess5, Ronald L Hornung6, Amitava Roy7, Jeffrey I Cohen1.   

Abstract

Epstein-Barr virus (EBV) infects B cells and ~95% of adults are infected. EBV glycoprotein gp42 is essential for entry of virus into B cells. EBV gp42 binds to the β1 chain of HLA-DQ, -DR, and -DP on B cells, and uses these molecules for infection. To investigate if certain HLA-DQ alleles are associated with EBV seronegativity, we recruited ~3,300 healthy adult blood donors, identified 106 EBV-seronegative individuals, and randomly selected a control group of EBV-seropositive donors from the donor pool. A larger than expected proportion of EBV-seronegative subjects were HLA-DQ β1 *04/*05 and *06/*06, and to a lesser extent, *02/*03, compared with the control group, while a larger than expected portion of EBV-seropositive persons were HLA-DQ β1 *02/*02. We examined the ability of EBV gp42 to bind to different HLA-DQ molecules using human and mouse cells stably expressing these alleles. EBV gp42 bound less effectively to cells expressing HLA-DQ β1 *04/*05, *06/*06, or *03/*03 than to cells expressing HLA-DQ β1 *02/*02. These data are consistent with our observations of increased EBV seronegativity with DQ β1 *04/*05 or *06/*06 alleles. These findings emphasize the importance of a single genetic locus (HLA-DQ β1) to influence infectivity with EBV.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28239644      PMCID: PMC5313076          DOI: 10.1172/jci.insight.85687

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  41 in total

1.  Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Sinéad Keating; Raquel Gomez; Kees L M C Franken; Tom H M Ottenhoff; Melanie Spriggs; Ton N Schumacher; Lindsey M Hutt-Fletcher; Martin Rowe; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Epstein-Barr virus and virus human protein interaction maps.

Authors:  Michael A Calderwood; Kavitha Venkatesan; Li Xing; Michael R Chase; Alexei Vazquez; Amy M Holthaus; Alexandra E Ewence; Ning Li; Tomoko Hirozane-Kishikawa; David E Hill; Marc Vidal; Elliott Kieff; Eric Johannsen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-19       Impact factor: 11.205

3.  The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation.

Authors:  M K Spriggs; R J Armitage; M R Comeau; L Strockbine; T Farrah; B Macduff; D Ulrich; M R Alderson; J Müllberg; J I Cohen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes.

Authors:  Q Li; M K Spriggs; S Kovats; S M Turk; M R Comeau; B Nepom; L M Hutt-Fletcher
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes.

Authors:  Jason Greenbaum; John Sidney; Jolan Chung; Christian Brander; Bjoern Peters; Alessandro Sette
Journal:  Immunogenetics       Date:  2011-02-09       Impact factor: 2.846

6.  Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.

Authors:  Britta Höcker; Helmut Fickenscher; Henri-Jacques Delecluse; Stephan Böhm; Uta Küsters; Paul Schnitzler; Martin Pohl; Ulrike John; Markus J Kemper; Henry Fehrenbach; Marianne Wigger; Martin Holder; Monika Schröder; Heiko Billing; Alexander Fichtner; Reinhard Feneberg; Anja Sander; Sabine Köpf-Shakib; Caner Süsal; Burkhard Tönshoff
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

7.  Exceptional stability of the HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus.

Authors:  R A Ettinger; A W Liu; G T Nepom; W W Kwok
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

8.  Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

Authors:  Henry H Balfour; Oludare A Odumade; David O Schmeling; Beth D Mullan; Julie A Ed; Jennifer A Knight; Heather E Vezina; William Thomas; Kristin A Hogquist
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

9.  Characteristics of Epstein-Barr virus envelope protein gp42.

Authors:  Pamela L Shaw; Austin N Kirschner; Theodore S Jardetzky; Richard Longnecker
Journal:  Virus Genes       Date:  2010-02-17       Impact factor: 2.332

10.  I-TASSER server for protein 3D structure prediction.

Authors:  Yang Zhang
Journal:  BMC Bioinformatics       Date:  2008-01-23       Impact factor: 3.169

View more
  4 in total

1.  Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense.

Authors:  Shu-Chen Hung; Tieying Hou; Wei Jiang; Nan Wang; Shuo-Wang Qiao; I-Ting Chow; Xiaodan Liu; Sjoerd H van der Burg; David M Koelle; William W Kwok; Ludvig M Sollid; Elizabeth D Mellins
Journal:  J Immunol       Date:  2019-03-29       Impact factor: 5.422

2.  Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature.

Authors:  Joanne R Winter; Charlotte Jackson; Joanna Ea Lewis; Graham S Taylor; Olivia G Thomas; Helen R Stagg
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

3.  Epstein-Barr Virus and the Human Leukocyte Antigen Complex.

Authors:  Qingxue Li; Jeffrey I Cohen
Journal:  Curr Clin Microbiol Rep       Date:  2019-07-08

4.  HLA-DPB1 and Epstein-Barr virus gp42 protein jointly contribute to the development of Hodgkin lymphoma.

Authors:  Hongyu Li; Dan Liu; Xun Li
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.